JP2025508665A5 - - Google Patents
Info
- Publication number
- JP2025508665A5 JP2025508665A5 JP2024543900A JP2024543900A JP2025508665A5 JP 2025508665 A5 JP2025508665 A5 JP 2025508665A5 JP 2024543900 A JP2024543900 A JP 2024543900A JP 2024543900 A JP2024543900 A JP 2024543900A JP 2025508665 A5 JP2025508665 A5 JP 2025508665A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210110349 | 2022-01-29 | ||
| CN202210110349.5 | 2022-01-29 | ||
| PCT/CN2023/073057 WO2023143351A1 (zh) | 2022-01-29 | 2023-01-19 | 糖皮质激素的药物偶联物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508665A JP2025508665A (ja) | 2025-04-10 |
| JP2025508665A5 true JP2025508665A5 (enExample) | 2026-01-23 |
Family
ID=87470772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543900A Pending JP2025508665A (ja) | 2022-01-29 | 2023-01-19 | グルココルチコイドの薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250152722A1 (enExample) |
| EP (1) | EP4470569A1 (enExample) |
| JP (1) | JP2025508665A (enExample) |
| KR (1) | KR20240134329A (enExample) |
| CN (1) | CN118678972A (enExample) |
| CA (1) | CA3248953A1 (enExample) |
| MX (1) | MX2024009080A (enExample) |
| TW (1) | TW202340252A (enExample) |
| WO (1) | WO2023143351A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120282801A (zh) | 2022-12-28 | 2025-07-08 | 苏州盛迪亚生物医药有限公司 | 一种cd40结合分子的组合物及医药用途 |
| TW202506196A (zh) * | 2023-07-28 | 2025-02-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 含有糖皮質激素的抗體藥物偶聯物的藥物組合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| PT2990420T (pt) | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| KR102502640B1 (ko) | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2017062271A2 (en) * | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| RS62040B1 (sr) | 2016-06-02 | 2021-07-30 | Abbvie Inc | Agonist receptora glukokortikoida i njegovi imunokonjugati |
| EP3658192B1 (en) | 2017-12-01 | 2021-04-28 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| MA50259A1 (fr) | 2018-01-08 | 2021-07-29 | Regeneron Pharma | Stéroïdes et leurs conjugués-anticorps |
| MX2021001143A (es) | 2018-08-24 | 2021-04-12 | Jiangsu Hengrui Medicine Co | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. |
| JP2022517767A (ja) * | 2019-01-08 | 2022-03-10 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 無痕跡型リンカー及びそのタンパク質－コンジュゲート |
| EP3946415A1 (en) | 2019-03-29 | 2022-02-09 | Astrazeneca AB | Lipocalin mutein for treatment of asthma |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| TWI924779B (zh) * | 2021-02-04 | 2026-05-11 | 大陸商上海森輝醫藥有限公司 | 糖皮質激素受體激動劑的藥物偶聯物及其在醫藥上的應用 |
-
2023
- 2023-01-19 EP EP23746232.0A patent/EP4470569A1/en active Pending
- 2023-01-19 CA CA3248953A patent/CA3248953A1/en active Pending
- 2023-01-19 KR KR1020247025079A patent/KR20240134329A/ko active Pending
- 2023-01-19 WO PCT/CN2023/073057 patent/WO2023143351A1/zh not_active Ceased
- 2023-01-19 US US18/833,773 patent/US20250152722A1/en active Pending
- 2023-01-19 CN CN202380015740.XA patent/CN118678972A/zh active Pending
- 2023-01-19 JP JP2024543900A patent/JP2025508665A/ja active Pending
- 2023-01-19 TW TW112102805A patent/TW202340252A/zh unknown
- 2023-01-19 MX MX2024009080A patent/MX2024009080A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7467610B2 (ja) | カンプトテシン誘導体及びその複合体 | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| JP2023535598A5 (enExample) | ||
| JP5782479B2 (ja) | ＰＥＧ化ＡβＦＡＢ | |
| CA3175733A1 (en) | Pharmaceutical composition comprising antibody drug conjugate and use thereof | |
| JP2019031565A5 (enExample) | ||
| JP2024501894A5 (enExample) | ||
| JP2025524637A (ja) | 抗体薬物複合体及びその調製方法並びに使用 | |
| JP2020532562A (ja) | 生物学的製剤の粘度を低下させるための化合物 | |
| WO2023124963A1 (zh) | 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用 | |
| CN115501347A (zh) | 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021525059A5 (enExample) | ||
| JP2025504419A (ja) | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 | |
| JP2023536155A5 (enExample) | ||
| CN118475367A (zh) | 用于治疗和预防covid-19的组合物 | |
| JP2025535263A (ja) | 組成物およびその使用 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| JP2025508665A (ja) | グルココルチコイドの薬物複合体 | |
| RU2024124223A (ru) | Конъюгат на основе глюкокортикоидного лекарственного средства | |
| RU2858285C2 (ru) | Производное каптотецина и его конъюгат | |
| RU2840147C1 (ru) | Фармацевтическая композиция, содержащая конъюгат антитела и лекарственного средства, и ее применение | |
| RU2833323C1 (ru) | Конъюгат антитела против cea и аналога эксатекана и его фармацевтическое применение | |
| RU2025113325A (ru) | Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака | |
| WO2026046228A1 (zh) | 树枝状聚合物偶联物及其制备方法 | |
| WO2026092698A1 (zh) | 一种抗体-药物偶联物及其制备方法和用途 |